Compugen (CGEN) AI Stock Analysis
Compugen
(TASE:CGEN)
No summary available
Compugen (CGEN) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 187.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 32.53K
- Price to Earnings (P/E)
- 5.1
- Beta (1Y)
- 1.01
- Revenue Growth
- 193.15%
- EPS Growth
- ―
- Country
- Israel
- Employees
- 75
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Compugen Business Overview & Revenue Model
Company Description
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Is...
Compugen Earnings Call Summary
The call conveyed measurable progress across Compugen's pipeline and partnerships — notable trial milestones (MAIA interim due Q1 2027), encouraging partner data (rilvegostomig ASCO OS signal), strengthened cash runway into 2029, and material milestone/royalty upside from Gilead and AstraZeneca. Offsetting these positives are key uncertainties: MAIA's exploratory design and lowered control-arm PFS benchmark, absence of pre-readout FDA engagement, early-stage status and limited visibility for GS-0321 data, dependency on partner execution for value realization, and continued modest absolute revenues with ongoing net losses. Overall, the fundamentals improved and near-term clinical and financial visibility increased, but meaningful regulatory and partner-driven milestones remain future-dependent.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that the MAIA‑ovarian interim analysis (median PFS data) is expected by Q1 2027, estimating the blinded placebo control median PFS at ~4 months (citing recent European trial control arms at 2.8 months and historical PARP registration ~5.5 months) and defining clinically meaningful success as ≥6 months PFS; MAIA is an exploratory, placebo‑controlled randomized trial (COM701 monotherapy ~40 patients vs ~20 placebo) and is not powered as a registrational study. On the financial side, cash and equivalents were ~$125.3M as of June 30, 2026 with a cash runway into 2029 assuming no further inflows; Q2‑2026 revenue was ~$2.6M (vs ~$1.3M a year ago), R&D expense ~$6.3M (vs ~$5.6M), G&A ~$2.3M (vs ~$2.2M), and net loss ~ $7.0M or $0.07 per share (vs ~$7.3M or $0.08). Partnership and pipeline metrics highlighted include $90M received to date from Gilead for GS‑0321 (up to $758M additional milestones + single‑digit to low‑double‑digit royalties), AstraZeneca adding a 12th Phase III rilvegostomig trial and previously guiding a >$5B non‑risk‑adjusted peak‑year revenue potential (plus up to $195M in milestones and mid‑single‑digit tiered royalties), and AstraZeneca’s GEMINI hepatobiliary rilve combo showing 16.8 months OS versus historical <13 months.
Compugen Risk Analysis
Compugen disclosed 79 risk factors in its most recent earnings report. Compugen reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksCompugen Peers Comparison
Overall Rating
NVCT56Neutral
STTK45Neutral
NKTX42Neutral
CCCC41Neutral
ELTX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NVCT | 56Neutral | $603.26M | -14.11 | -169.47% | ― | ― | -13.52% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| STTK | 45Neutral | $558.02M | -10.90 | -43.57% | ― | -66.63% | 57.89% |
| NKTX | 42Neutral | $111.73M | -0.99 | -39.64% | ― | ― | -6.70% |
| CCCC | 41Neutral | $414.59M | -3.37 | -45.45% | ― | 2.33% | 36.86% |
| ELTX | 40Underperform | $45.51M | -0.79 | -1266.43% | ― | ― | 49.43% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:CGEN | Compugen | 623.20 | 63.10 | 11.27% | |
| NKTX | Nkarta, Inc. | 1.56 | -0.51 | -24.64% | |
| CCCC | C4 Therapeutics, Inc. | 3.37 | 0.89 | 35.89% | |
| STTK | Shattuck Labs, Inc. | 5.56 | 3.57 | 179.40% | |
| ELTX | Elicio Therapeutics, Inc | 1.68 | -7.57 | -81.84% | |
| NVCT | Nuvectis Pharma, Inc. | 18.48 | 12.12 | 190.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.